Navigation Links
Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
Date:5/18/2012

HACKENSACK, N.J., May 18, 2012 /PRNewswire/ -- Champions Oncology Inc. (OTC: CSBR) announced today that it has received U.S. Clinical Laboratory Improvement Amendment (CLIA) certification from the Maryland Department of Health and Mental Hygiene Office of Health Care Quality required for the company to conduct medical laboratory tests.

The Company's President, Ronnie Morris, MD commented, "Obtaining CLIA approval is a significant milestone for our Company. This approval validates the quality of our laboratory, which operates with a focus on providing high quality services. This certification will reinforce to both our patients and sponsors who utilize our technology that we are achieving the high standards we set as a Company."

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development a
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... the thinnest-possible semiconductor, a new class of nanoscale ... , The University of Washington researchers have demonstrated ... be connected in an atomically seamless fashion known ... basis for next-generation flexible and transparent computing, better ... "Heterojunctions are fundamental elements of electronic and photonic ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Mers CoV virus ... Replikin structures back to 2012.  This conservation and sharing ... of a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did ... Shrimp vaccine, both of which have been found to ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
(Date:8/26/2014)...  ViveBio, LLC a leading provider of products ... announced today that it has signed a distribution ... Knoxville, Tennessee to distribute ... United States . ViveST is the first ... biological specimen transport systems.  The technology enables easy, ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin Board: ... order for the international,distribution of the Resurgex(R) line in Greece. ...
... CAMBRIDGE, Mass., April 1, 2008 Abt ... Abt Bio-Pharma Solutions, Inc., a,wholly owned subsidiary of ... custom strategic, research and communication solutions for the,pharmaceutical, ... approach that blends decades of experience with wide,ranging ...
... MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... global biopharmaceutical company,focused on endocrine therapy and ... leading Canadian specialty pharmaceutical company, announced today,that, ... transactions under their,previously announced purchase and sale ...
Cached Biology Technology:Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... has named its awardee for this year,s Alan ... Brown University. Dunn,s work involves genome analyses ... He investigates the origins of biological complexity ... research holds clues about how complex multicellular organisms, ...
... This release is available in French . ... without exposing the healthy surrounding tissue to the medication,s toxic ... medical reality, thanks to the work of Professor Sylvain Martel, ... Known for being the world,s first researcher to have guided ...
... most controversial aspects in the sustainable management of golf courses. ... the practices relating to reclaimed water at one of the ... on the course receive 83% more water than they need. ... be justified from any perspective", Mara del Pino Palacios Daz, ...
Cached Biology News:Casey Dunn to receive NSF Waterman Award 2Casey Dunn to receive NSF Waterman Award 3World first -- Localized delivery of an anti-cancer drug by remote-controlled microcarriers 2Golf courses that reuse water irrigate too much 2Golf courses that reuse water irrigate too much 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: